Eisai Company, Ltd. and Minophagen Pharmaceutical Conclude License Agreement Concerning the Development and Commercialization of Cutaneous T-Cell Lymphoma Treatment Bexarotene in Asia, Oceania, the Middle East and Eastern Europe

Tokyo, Apr 2, 2012 (JCN Newswire) - Eisai Co., Ltd. and Minophagen Pharmaceutical Co., Ltd. announced today that they have concluded a license agreement concerning bexarotene (generic name), a treatment for cutaneous T-cell lymphoma (CTCL).